Short answer
aTYR PHARMA INC (ATYR) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$10M
- +47.2% YoY · +4.5% QoQ
- EPS (diluted)
- −$0.11
- +50.0% YoY · +0.0% QoQ
Source: XBRL data from the aTYR PHARMA INC (ATYR) Q2 2026 10-Q on SEC EDGAR. USD.
aTYR PHARMA INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New capital risk triggered by planned Phase 3 efzofitimod study and August restructuring reducing workforce approximately 60% to 20 employees
- Regulatory approval risk after FDA deemed EFZO-FIT failed and raised safety concerns over higher dose and narrower patient population
- Clinical execution risk from planned dosing increase to 5.0 mg/kg every three weeks versus every four weeks previously
- Liquidity risk with $58.9 million in cash, restricted cash and available-for-sale investments as of June 30, 2026
- Financial sustainability risk with $21.1 million six-month net loss and $627.3 million accumulated deficit
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other aTYR PHARMA INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.